Category: prescription drugs

Health Spending Issues to Watch This Year

KFF and the Peterson Center on Healthcare examine market trends contributing to rising health costs and identify several potential federal and state policy issues to watch throughout 2025, including high-cost drugs, federal funding cuts, and workforce …

KFF Health News’ ‘What the Health?’: American Health Gets a Pink Slip

The Department of Health and Human Services underwent an unprecedented purge this week, as thousands of employees from the National Institutes of Health, the FDA, the Centers for Disease Control and Prevention, and other agencies were fired, placed on administrative leave, or offered transfers to far-flung Indian Health Service facilities. Altogether, the layoffs mean the federal government, in a single day, shed hundreds if not thousands of combined years of health and science expertise. Lauren Weber of The Washington Post, Rachel Cohrs Zhang of Bloomberg News, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News’ Julie Rovner to discuss this enormous breaking story and more. Also this week, Rovner interviews KFF Health News’ Julie Appleby, who reported and wrote the latest “Bill of the Month” feature about a short-term health plan and a very expensive colonoscopy.

KFF Health News’ ‘What the Health?’: Federal Health Work in Flux

It’s the Trump administration vs. the federal courts, as the Department of Government Efficiency continues to try to cancel federal contracts and programs and fire workers. But in the haste to cut things, jobs and programs are being eliminated even if they align with the new administration’s goal to “Make America Healthy Again.” Jessie Hellmann of CQ Roll Call, Sarah Karlin-Smith of the Pink Sheet, and Rachel Roubein of The Washington Post join KFF Health News’ Julie Rovner to discuss these stories and more.

KFF Health News’ ‘What the Health?’: Federal Health Work in Flux

It’s the Trump administration vs. the federal courts, as the Department of Government Efficiency continues to try to cancel federal contracts and programs and fire workers. But in the haste to cut things, jobs and programs are being eliminated even if they align with the new administration’s goal to “Make America Healthy Again.” Jessie Hellmann of CQ Roll Call, Sarah Karlin-Smith of the Pink Sheet, and Rachel Roubein of The Washington Post join KFF Health News’ Julie Rovner to discuss these stories and more.

Pain Clinics Made Millions From ‘Unnecessary’ Injections Into ‘Human Pin Cushions’

Pain MD, which once ran as many as 20 clinics across three states, gave chronic-pain patients about 700,000 total injections near their spines, according to court documents. Last year, federal prosecutors proved at trial that the shots were medically unnecessary and part of an extensive fraud scheme.

Top California Democrats Clash Over How To Rein In Drug Industry Middlemen

Frustrated by spiraling drug costs, California lawmakers want to increase oversight of pharmaceutical industry intermediaries known as pharmacy benefit managers. It’s unclear whether they can persuade Gov. Gavin Newsom to get on board.

KFF Prescription Drug Advertisements Poll: January 2025

KFF’s January 2025 Prescription Drug Advertisements Poll looks at the public’s experiences with prescription drug advertisements, whether they’ve talked to a doctor about advertised drugs, and how this has influenced the care they receive.

KFF Health Tracking Poll: Public Weighs Health Care Spending and Other Priorities for Incoming Administration

With the incoming Trump administration and Republican-led Congress looking to ways to reduce federal spending, this Poll finds that the Medicare and Medicaid programs remain broadly popular, and more people favor more spending on those programs than le…

‘Bill of the Month’: The Series That Dissects and Slashes Medical Bills

Since 2018, readers and listeners sent KFF Health News-NPR’s “Bill of the Month” thousands of questionable bills. Our crowdsourced investigation paved the way for landmark legislation and highlighted cost-saving strategies for all patients.

How Medicare Negotiated Drug Prices Compare to Other Countries

This analysis finds that Medicare’s negotiated prices for 10 high-expenditure prescription drugs are lower than what private Medicare drug plans had been paying, but still much higher than the prices available in 11 other wealthy nations.. It is availa…